MoneyThe story, in brief
Why Pfizer And Eli Lilly Are Betting On This $1.3 Billion AI Drug Discovery Startup
$3.4B. That's Chai Discovery's new valuation as Pfizer and Eli Lilly double down on AI drug discovery.
The KeyNews take
Why it matters
Pharmaceutical giants are validating AI-driven drug discovery as a category by backing Chai with serious capital. The $400M raise signals that AI models for biology/antibody design are moving from R&D curiosity to mission-critical pipeline tools—and investors see defensible moats in vertical AI.
The key facts
5 to knowChai Discovery raising $400M at $3.4B valuation
Previous valuation: $1.3B
Backing from Pfizer and Eli Lilly (major pharma validation)
Focus: antibody AI model for drug discovery
Use case: deploying with major drugmakers to find new therapies
Go to the source
Forbes Innovationforbes.com
Publisher excerpt: Chai Discovery is working with major drugmakers to use its latest antibody AI model to find new therapies. Now it’s in talks to raise $400 million more VC funding at a $3.4 billion valuation, Forbes has learned.